Intraspinal Steroid Therapy
Neurol 31:168-171, Bernat,J.L., 1981
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Trauma and Multiple Sclerosis:A Population-Based Cohort Study from Olmsted County, Minnesota
Neurol 43:1878-1882, 18711993., Siva,A.,et al, 1993
The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis
NEJM 329:1764-1769, 1808-18101993., Beck,R.W.,et al, 1993
Surgical Treatment of Cervical Spondylotic Myelopathy:Time for a Controlled Trial
Neurol 42:5-13, Rowland,L.P., 1992
Lhermitte's Sign in Multiple Sclerosis:A Clinical Survey & Review of the Literature
JNNP 45:308-312, Kanchandani,R.,et al, 1982
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
The Changing Management of Acute Optic Neuritis
Neuro Ophth, Chap 5, 6:44, 1972 Ed. J. L. Smith (Book) ., Lubow,M.,et al, 1972
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Inclusion of Optic Nerve Involvement in Dissemination in Space Criteria for Multiple Sclerosis
Neurol 91:e1130-e1134,545, Brownlee, W.J.,et al, 2018
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Pediatric Optic Neuritis: Brain MRI Abnormalities and Risk of Multiple Sclerosis
Neurol 72:881-885, Bonhomme,G.R.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006
Is Optic Neuritis More Benign Than Other First Attacks in Multiple Sclerosis?
Ann Neurol 57:210-215, Tintore, M., et al, 2005
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Role of Magnetic Resonance Imaging Within Diagnostic Criteria for Multiple Sclerosis
Ann Neurol 56:273-278, Miller,D.H.,et al, 2004
Neurologic Impairment 10 Years After Optic Neuritis
Arch Neurol 61:1386-1389, Optic Neuritis Study Group, 2004
The Natural History of Recurrent Optic Neuritis
Arch Neurol 61:1401-1405, Pirko,I.,et al, 2004
Long-Term Brain Magnetic Resonance Imaging Changes After Optic Neuritis in Patients Without Clinically Definite Multiple Sclerosis
Arch Neurol 61:1538-1541, Optic Neuritis Study Group, 2004
The Bioavailability of IV Methylprednisolone and Oral Prednisone in Multiple Sclerosis
Neurol 63:1079-1080, Morrow,S.A.,et al, 2004
Clinical Characteristics of African Americans vs Caucasian Americans with Multiple Sclerosis
Neurol 63:2039-2045, Bree,B.A.C.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Spinal Cord MRI in Clinically Isolated Optic Neuritis
JNNP 74:1577-1580, Dalton,C.M.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Optic Neuritis in Multiple Sclerosis: An Update
The Neurologist 6:205-213, Chan,J.W., 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Optic Neuritis as Onset Manifestations of Multiple Sclerosis
Neurol 53:473-478, Sorensen,T.L.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999